en
Scientific article
English

Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer's Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial

Published inJournal of Alzheimer's Disease, vol. 61, no. 1, p. 435-457
Publication date2018
Abstract

LMTM is being developed as a treatment for AD based on inhibition of tau aggregation.

Keywords
  • Aged
  • Aged, 80 and over
  • Alzheimer Disease/diagnostic imaging/drug therapy
  • Antipsychotic Agents/therapeutic use
  • Cohort Studies
  • Double-Blind Method
  • Female
  • Humans
  • International Cooperation
  • Male
  • Mental Status and Dementia Tests
  • Methylene Blue/analogs & derivatives/therapeutic use
  • Middle Aged
  • Treatment Outcome
Citation (ISO format)
WILCOCK, Gordon K et al. Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer’s Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial. In: Journal of Alzheimer’s Disease, 2018, vol. 61, n° 1, p. 435–457. doi: 10.3233/JAD-170560
Main files (1)
Article (Published version)
accessLevelRestricted
Identifiers
ISSN of the journal1387-2877
358views
0downloads

Technical informations

Creation02/11/2019 5:36:00 PM
First validation02/11/2019 5:36:00 PM
Update time03/15/2023 4:20:50 PM
Status update03/15/2023 4:20:48 PM
Last indexation01/17/2024 5:20:38 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack